Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: A pilot study

Annals of Nuclear Medicine

Volumn 25, Issue 5, 2011, Pages 339-345

  Minagawa, Yumiko ^a   Shizukuishi, Kazuya ^a   Koike, Izumi ^a   Horiuchi, Choichi ^a   Watanuki, Kei ^a   Hata, Masaharu ^a   Omura, Motoko ^a   Odagiri, Kazumasa ^a   Tohnai, Iwai ^a   Inoue, Tomio ^a   Tateishi, Ukihide ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

62Cu ATSM; Head and neck cancer; Hypoxia; PET; Response

Indexed keywords

ATSM CU 62; CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINATE CALCIUM; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; METHOTREXATE; TRACER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER SIZE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG RESPONSE; DRUG UPTAKE; FEMALE; GINGIVA TUMOR; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; HYPOXEMIA; LARYNX CARCINOMA; MALE; MAXILLA SINUS CARCINOMA; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; PHARYNX CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TUMOR HYPOXIA;

AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CELL HYPOXIA; COPPER RADIOISOTOPES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; THIOSEMICARBAZONES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 80052338025     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-011-0471-5     Document Type: Article

References (21)

1. Chin D, Boyle GM, Porceddu S, Theile DR, Parsons PG, et al. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther. 2006;6:1111-8. (Pubitemid 44203388)
2. Fremgen AM, Bland KI, McGinnis LS Jr, Eyre HJ, McDonald CJ, Menck HR, et al. Clinical highlights from the National Cancer Data Base, 1999. CA Cancer J Clin. 1999;49:145-58. (Pubitemid 29353928)
3. Laskar SG, Agarwal JP, Srinivas C, Dinshaw KA. Radiotherapeutic management of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2006;6:405-17. (Pubitemid 44192922)
4. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-60. (Pubitemid 27339632)
5. Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, et al. Evaluation of 62Cu labeled diacetyl-bis(N4- methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med. 2000;14:323-8.
6. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum. 2008;51: 1641-8.
7. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-8. (Pubitemid 36338289)
8. Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171-82. (Pubitemid 32184623)
9. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 2004;9(Suppl 5):31-40.
10. Wouters A, Pauwels B, Lardon F, Vermorken JB. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist. 2007;12: 690-712. (Pubitemid 47036204)
11. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-41. (Pubitemid 44497258)
12. Grönroos T, Eskola O, Lehtiö K, Minn H, Marjamäki P, Bergman J, et al. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med. 2001;42:1397-404. (Pubitemid 32852618)
13. Padera TP, Stoll BR, Tooredman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature. 2004;427:695. (Pubitemid 38294577)
14. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18Fmisonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-60. (Pubitemid 43073432)
15. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844-50. (Pubitemid 36734203)
16. Kitagawa Y, Sadato N, Azuma H, Ogasawara T, Yoshida M, Ishii Y, et al. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med. 1999;40:1132-7. (Pubitemid 29315503)
17. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2- deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59: 1295-300. (Pubitemid 38954050)
18. Ichiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. J Nucl Med. 1991;32(9):1655-60.
19. Soto DE, Kessler ML, Piert M, Eisbruch A. Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother Oncol. 2008;89(1):13-8.
20. La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74(5): 1335-41.
21. Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, et al. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer. J Nucl Med. 2009;50(12):1948-53.